[ad_1]
Exchange with Youth This afternoon, December 16, the leader of the Military Medical Academy (Department of Military Medicine, Ministry of Defense) said that, at 8:00 am tomorrow, December 17, the clinical trials unit of the academy will officially inject the Covid Nano Covax vaccines. volunteers first.
This is the first phase of the Covid-19 vaccine clinical trial program implemented by the Military Medical Academy, the tested vaccine is researched and developed by Nanogen Company (Ho Chi Minh City).
In phase 1 of the study, 60 people ages 18 to 50 will be vaccinated at doses of 25 mcg and 75 mcg. All subjects participating in the phase 1 study will receive 2 intramuscular injections of the Covid-19 vaccine, the interval between 2 injections is 28 days. To ensure the safety of the study participants, during the recruitment period of 60 participants, the safety assessment was carried out according to the escalating dose detection design.
During the first injection tomorrow morning, the first group of six people is expected to receive the vaccine. The volunteers who originally injected the first injections were volunteers under the age of 40. On December 17, the study will test the vaccine for 6 people in the 25 mcg dose group.
The total value of insurance benefits for volunteers is 20 billion VND, a maximum of 100 million VND / person if risks are identified due to Nano Covax vaccination. There were 200 people registered to participate in the vaccination, after 7 days the Military Medical Academy announced the recruitment of volunteers for the study.
Today, the production unit completed the transport of the vaccine to the injection site. This vaccine is stored in conditions between 2 and 8 degrees C.
This afternoon, the National Steering Committee for the Control of Covid-19 Diseases said that no new cases were recorded during the day. 18,378 people who have been in close contact with the case and who enter from the area of the epidemic are under medical monitoring for the prevention of the Covid-19 epidemic.
[ad_2]